Profile data is unavailable for this security.
About the company
Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). It is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.
- Revenue in GBP (TTM)2.33bn
- Net income in GBP219.96m
- Incorporated2005
- Employees8.97k
- LocationHikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
- Phone+44 207 399 2760
- Fax+44 207 399 2761
- Websitehttps://www.hikma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | 169.11m | -350.23m | 3.66bn | 550.00 | -- | -- | -- | 21.62 | -2.64 | -2.64 | 1.24 | -5.81 | 0.3376 | -- | -- | 398,407.30 | -71.11 | -72.44 | -89.59 | -89.72 | 98.91 | 94.41 | -210.62 | -1,225.66 | -- | -9.63 | 2.70 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| ALK-Abello A/S | 583.10m | 77.67m | 3.69bn | 2.81k | 52.29 | 7.28 | 32.95 | 6.32 | 3.09 | 3.09 | 22.91 | 22.22 | 0.7673 | 1.27 | 6.11 | 1,834,278.00 | 10.22 | 3.50 | 12.56 | 4.37 | 63.42 | 60.66 | 13.32 | 5.07 | 1.29 | 479.50 | 0.0934 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| IPCA Laboratories Ltd | 753.26m | 52.90m | 3.69bn | 17.34k | 69.73 | -- | 42.39 | 4.90 | 22.74 | 22.74 | 323.71 | -- | -- | -- | -- | 4,737,502.00 | -- | 10.33 | -- | 13.52 | 67.08 | 59.16 | 6.84 | 12.25 | -- | 15.41 | -- | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| Krka d.d. Novo Mesto | 1.57bn | 307.16m | 3.74bn | 11.79k | 11.48 | 1.75 | 9.62 | 2.38 | 11.85 | 11.85 | 60.59 | 77.51 | 0.6476 | 1.40 | 3.59 | 160,399.30 | 12.64 | 12.64 | 14.86 | 15.12 | 56.10 | 57.29 | 19.52 | 18.71 | 3.04 | -- | 0.005 | 59.21 | 5.18 | 6.28 | -13.58 | 12.45 | 8.35 | 18.57 |
| Humanwell Healthcare Group Co Ltd | 2.78bn | 212.57m | 3.76bn | 17.68k | 17.47 | 1.93 | -- | 1.35 | 1.21 | 1.21 | 15.87 | 10.95 | 0.6902 | 3.80 | 2.74 | 1,445,825.00 | 7.13 | 6.20 | 13.12 | 12.72 | 45.59 | 42.82 | 10.33 | 9.84 | 1.21 | 12.09 | 0.3171 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
| Rohto Pharmaceutical Co Ltd | 1.41bn | 153.84m | 3.99bn | 7.26k | 25.11 | 2.95 | 19.88 | 2.83 | 132.56 | 132.56 | 1,215.22 | 1,129.95 | 0.7642 | 2.21 | 4.37 | 38,300,730.00 | 8.42 | 8.54 | 11.70 | 11.79 | 57.76 | 58.59 | 11.02 | 10.30 | 1.27 | -- | 0.1513 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
| Corcept Therapeutics Incorporated | 485.09m | 109.45m | 4.05bn | 352.00 | 39.43 | 8.18 | 36.69 | 8.34 | 1.27 | 1.27 | 5.64 | 6.12 | 0.9121 | 1.26 | 13.32 | 1,785,668.00 | 20.58 | 21.17 | 25.10 | 23.85 | 98.44 | 98.52 | 22.56 | 27.23 | 3.64 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Avidity Biosciences Inc | 8.18m | -194.83m | 4.07bn | 253.00 | -- | 4.01 | -- | 497.65 | -2.95 | -2.95 | 0.1231 | 11.17 | 0.0108 | -- | 17.92 | 41,893.28 | -25.78 | -31.61 | -27.61 | -34.45 | -- | -- | -2,381.82 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| GlaxoSmithKline Pharmaceuticals Limited | 326.57m | 61.92m | 4.08bn | 3.21k | 66.28 | 26.58 | 59.81 | 12.49 | 39.60 | 39.60 | 209.31 | 98.74 | 1.01 | 2.59 | 14.85 | 11,088,370.00 | 19.24 | 11.01 | 36.09 | 17.88 | 61.70 | 55.77 | 18.96 | 12.25 | 1.38 | 554.80 | 0.0088 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 1.67bn | 471.35m | 4.10bn | 11.60k | 8.57 | 1.67 | 7.18 | 2.46 | 1,248.46 | 1,248.46 | 4,419.54 | 6,425.20 | 0.5959 | 1.36 | 3.77 | 69,931,480.00 | 16.92 | 11.64 | 19.01 | 13.28 | 68.64 | 58.18 | 28.40 | 18.93 | 2.03 | -- | 0.0454 | 39.94 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.94 |
| Hikma Pharmaceuticals Plc | 2.33bn | 219.96m | 4.11bn | 8.97k | 18.82 | 2.32 | 11.07 | 1.76 | 0.9839 | 0.9839 | 10.43 | 7.98 | 0.6374 | 1.77 | 3.38 | 259,669.90 | 6.13 | 8.19 | 8.47 | 11.30 | 47.40 | 50.29 | 9.61 | 13.77 | 0.9775 | 7.81 | 0.3568 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 14.03 |
| Glenmark Pharmaceuticals Ltd | 1.10bn | -144.30m | 4.40bn | 14.99k | -- | -- | -- | 3.99 | -55.78 | -46.50 | 425.96 | -- | -- | -- | -- | 8,020,026.00 | -- | 1.02 | -- | 1.43 | 63.93 | 59.47 | -12.71 | 1.43 | -- | 1.78 | -- | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
Data as of Nov 05 2024. Currency figures normalised to Hikma Pharmaceuticals PLC's reporting currency: UK Pound GBX
25.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Dec 2023 | 11.56m | 5.21% |
| JPMorgan International Bank Ltd.as of 01 Oct 2024 | 10.75m | 4.84% |
| Capital Research & Management Co. (World Investors)as of 01 Oct 2024 | 7.04m | 3.17% |
| BlackRock Advisors (UK) Ltd.as of 31 Dec 2023 | 6.15m | 2.77% |
| Mawer Investment Management Ltd.as of 30 Jun 2024 | 4.86m | 2.19% |
| The Vanguard Group, Inc.as of 01 Oct 2024 | 4.23m | 1.90% |
| Royal London Asset Management Ltd.as of 01 Oct 2024 | 3.25m | 1.46% |
| Polar Capital LLPas of 30 Sep 2024 | 3.06m | 1.38% |
| Threadneedle Asset Management Ltd.as of 31 Jul 2024 | 3.01m | 1.36% |
| Norges Bank Investment Managementas of 01 Oct 2024 | 2.67m | 1.20% |
More ▼
Data from 30 Jun 2024 - 01 Oct 2024Source: FactSet Research Systems Inc.
